2 /PRNewswire/ -- The latest analyses of the landmark Carvedilol or Metoprolol European Trial (COMET) have shown further significant benefits for chronic heart failure (CHF) patients treated with the non-selective beta blocking agent
carvedilol compared to those treated with the beta-1 selective beta blocker, metoprolol(1).
Strasbourg, France -- Strasbourg, France, June 23 /PRNewswire/ -- Patients with chronic heart failure (CHF) treated with the non-selective beta blocking agent
, carvedilol (Dilatrend(r)), gained a highly significant survival benefit (17 per cent, p=0.
Despite compelling evidence about their benefits from previous studies, beta blocking agents are dramatically under-utilized in the treatment of heart failure.
Coreg(R) First Beta Blocking Agent to Demonstrate a Survival Benefit in
Landmark study results reported by researchers showed that the beta blocking agent Coreg(R) (carvedilol) decreased mortality rates by 35 percent in patients with the most advanced stage of heart failure who were already taking standard therapy.